S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Li Auto smashes estimates proving EVs can be profitable
Get ready for Christmas shopping-sprees with these 2 winners

Balchem Stock Price, News & Analysis (NASDAQ:BCPC)

$122.71
-0.52 (-0.42%)
(As of 11/28/2023 ET)
Compare
Today's Range
$120.87
$123.14
50-Day Range
$115.08
$130.30
52-Week Range
$110.74
$143.68
Volume
64,728 shs
Average Volume
90,656 shs
Market Capitalization
$3.96 billion
P/E Ratio
38.47
Dividend Yield
0.58%
Price Target
$135.00

Balchem MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.0% Upside
$135.00 Price Target
Short Interest
Healthy
0.80% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.54
Upright™ Environmental Score
News Sentiment
1.64mentions of Balchem in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$499,966 Sold Last Quarter
Proj. Earnings Growth
10.56%
From $3.41 to $3.77 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Basic Materials Sector

30th out of 166 stocks

Chemicals & Allied Products Industry

4th out of 15 stocks


BCPC stock logo

About Balchem Stock (NASDAQ:BCPC)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; single use canisters for sterilizing re-usable devices; and ammonia. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in Montvale, New Jersey.

BCPC Stock Price History

BCPC Stock News Headlines

Balchem Corp BCPC
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Balchem Q3: A Solid Performer Is Seeing A Soft 2023
Here's what Wall Street expects from Balchem's earnings
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Earnings Outlook For Balchem
Balchem Q3 2023 Earnings Preview
The Returns At Balchem (NASDAQ:BCPC) Aren't Growing
Balchem (NASDAQ: BCPC)
Q2 2023 Balchem Corp Earnings Call
See More Headlines
Receive BCPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Balchem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2023
Today
11/28/2023
Ex-Dividend for 1/16 Dividend
12/28/2023
Fiscal Year End
12/31/2023
Dividend Payable
1/16/2024
Next Earnings (Estimated)
2/23/2024

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
Specialty Chemicals
Current Symbol
NASDAQ:BCPC
CUSIP
05766520
CIK
9326
Employees
1,340
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$135.00
High Stock Price Target
$135.00
Low Stock Price Target
$135.00
Potential Upside/Downside
+10.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$105.37 million
Pretax Margin
14.01%

Debt

Sales & Book Value

Annual Sales
$942.36 million
Cash Flow
$4.88 per share
Book Value
$29.20 per share

Miscellaneous

Free Float
31,670,000
Market Cap
$3.96 billion
Optionable
Optionable
Beta
0.68

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Theodore L. Harris (Age 58)
    Chairman, CEO & President
    Comp: $2.33M
  • Mr. Carl Martin Bengtsson (Age 45)
    Executive VP, CFO & Treasurer
    Comp: $864.13k
  • Ms. Hatsuki Miyata (Age 47)
    Executive VP, General Counsel & Secretary
    Comp: $618.21k
  • Mr. Jonathan H. Griffin (Age 47)
    Senior VP and GM of Animal Nutrition & Health
    Comp: $624.01k
  • Mr. Martin Luther Reid (Age 55)
    Senior VP & Chief Supply Chain Officer
    Comp: $672.26k
  • Mr. William A. Backus CPA (Age 57)
    VP & CAO
    Comp: $560.79k
  • Mr. Michael R. Sestrick Ph.D. (Age 59)
    Senior VP & CTO
  • Mr. Brent Tignor (Age 45)
    Senior VP & Chief Human Resources Officer
  • Mr. Frederic Boned (Age 45)
    Senior VP and GM of Human Nutrition & Health
  • Mr. Job L. van Gunsteren (Age 47)
    Senior VP & GM of Specialty Products














BCPC Stock Analysis - Frequently Asked Questions

Should I buy or sell Balchem stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Balchem in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCPC shares.
View BCPC analyst ratings
or view top-rated stocks.

What is Balchem's stock price target for 2024?

1 Wall Street analysts have issued 12 month price targets for Balchem's shares. Their BCPC share price targets range from $135.00 to $135.00. On average, they expect the company's stock price to reach $135.00 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price.
View analysts price targets for BCPC
or view top-rated stocks among Wall Street analysts.

How have BCPC shares performed in 2023?

Balchem's stock was trading at $122.11 on January 1st, 2023. Since then, BCPC stock has increased by 0.5% and is now trading at $122.71.
View the best growth stocks for 2023 here
.

Are investors shorting Balchem?

Balchem saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 256,800 shares, an increase of 19.9% from the October 31st total of 214,200 shares. Based on an average daily volume of 85,200 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.8% of the shares of the company are short sold.
View Balchem's Short Interest
.

When is Balchem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 23rd 2024.
View our BCPC earnings forecast
.

How were Balchem's earnings last quarter?

Balchem Co. (NASDAQ:BCPC) announced its quarterly earnings data on Friday, October, 27th. The basic materials company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.91 by $0.01. The basic materials company had revenue of $229.95 million for the quarter, compared to analysts' expectations of $238.47 million. Balchem had a net margin of 11.15% and a trailing twelve-month return on equity of 10.48%.

How often does Balchem pay dividends? What is the dividend yield for Balchem?

Balchem announced an annual dividend on Thursday, October 5th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.398 per share on Tuesday, January 16th. This represents a yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 28th.
Read our dividend analysis for BCPC
.

Is Balchem a good dividend stock?

Balchem (NASDAQ:BCPC) pays an annual dividend of $0.71 per share and currently has a dividend yield of 0.58%. The company has been increasing its dividend for 14 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 22.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BCPC will have a dividend payout ratio of 18.83% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BCPC.

What is Dino A. Rossi's approval rating as Balchem's CEO?

25 employees have rated Balchem Chief Executive Officer Dino A. Rossi on Glassdoor.com. Dino A. Rossi has an approval rating of 85% among the company's employees. 62.0% of employees surveyed would recommend working at Balchem to a friend.

What other stocks do shareholders of Balchem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Balchem investors own include Ecolab (ECL), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ), Lowe's Companies (LOW), Altria Group (MO), NVIDIA (NVDA), AT&T (T), Analog Devices (ADI) and Bristol-Myers Squibb (BMY).

Who are Balchem's major shareholders?

Balchem's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.34%), Schroder Investment Management Group (1.74%), Morgan Stanley (1.63%), Clearbridge Investments LLC (1.61%), Ameriprise Financial Inc. (1.25%) and Northern Trust Corp (1.24%). Insiders that own company stock include David B Fischer, Gunsteren Job Leonard Van, Michael Robert Sestrick and William A Backus.
View institutional ownership trends
.

How do I buy shares of Balchem?

Shares of BCPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Balchem have any subsidiaries?
The following companies are subsidiares of Balchem: Aberco Inc., Aberco Inc., Albion Laboratories Inc., Albion Laboratories Inc., BCP Ingredients Inc., Balchem BV, Balchem Italia Srl, Balchem Ltd., Balchem NV, Balchem Pte Ltd., Balchem Pty Ltd., Balchem Sdn Bhd, Bioscreen technologies, Chemogas Holding NV, Chol-Mix Kft, Innovative Food Processors, SensoryEffects, SensoryEffects Cereal Systems Inc., SensoryEffects Inc., Stereo Gas Philippines Inc., and Zumbro River Brand Inc..
Read More
This page (NASDAQ:BCPC) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -